Aurora kinase A · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Aurora kinase A shows late clinical disease relevance led by unspecified peripheral T-cell lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14965. Start with unspecified peripheral T-cell lymphoma, then reuse UniProt O14965 as the stable protein anchor across project notes and exports.
Start with unspecified peripheral T-cell lymphoma, then reuse UniProt O14965 as the stable protein anchor across project notes and exports.
Aurora kinase A shows late clinical disease relevance led by unspecified peripheral T-cell lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with unspecified peripheral T-cell lymphoma because it currently carries late clinical support. Linked drugs include ALISERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyAurora kinase A
Review this target as Aurora kinase A, mapped to UniProt O14965. Sequence length is 403 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Aurora kinase A as ChEMBL target CHEMBL4722, mapped to UniProt O14965. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Aurora kinase A is the right protein anchor across sources, using UniProt O14965 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why unspecified peripheral T-cell lymphoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Aurora kinase A |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O14965 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Aurora kinase A |
| UniProt Accession | O14965 |
| Component Type | Protein |
| Sequence Length | 403 aa |
Aurora kinase A
Review this target as Aurora kinase A, mapped to UniProt O14965. Sequence length is 403 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Aurora kinase A shows late clinical disease relevance led by unspecified peripheral T-cell lymphoma. 5 more disease programs remain visible in the same review block.
Start review with unspecified peripheral T-cell lymphoma because it currently carries late clinical support. Linked drugs include ALISERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4225923 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4227082 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL3685304 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL4443279 | 10.92 | IC50 | 0.012 | Preclinical |
| CHEMBL4462759 | 10.92 | IC50 | 0.012 | Preclinical |
| CHEMBL4476212 | 10.92 | IC50 | 0.012 | Preclinical |
| CHEMBL3675462 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3675439 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3680540 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL483158 | 10.4 | IC50 | 0.04 | Clinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 970 | 2,525 | 7.2 |
| cell-based format | 266 | 391 | 7.1 |
| assay format | 137 | 275 | 7.2 |
| subcellular format | 34 | 35 | 7.2 |
| organism-based format | 1 | 0 | — |
| tissue-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 6 | 1 | 7.4 |
| assay format | 2 | 420 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 6 | 7.3 |
| single protein format | 3 | 5 | 6.7 |
| cell-based format | 1 | 0 | — |